Perrigo Company plc Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax of -$9.10 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax · last filed 2021-03-01
- Perrigo Company plc other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2018 was -$9.10M, a 196.81% decline from fiscal 2017.
- Perrigo Company plc other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2017 was $9.40M.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 12 month |
|---|---|
| 2018-12-31 | -$9.10M 10-K · filed 2021-03-01 |
| 2017-12-31 | $9.40M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |